Ruud Coumans
Project Leader Byondis
After obtaining a PhD in supramolecular chemistry in 2006 followed by a brief postdoctoral stay in academia working on self-healing materials, Ruud Coumans started at Syntarga to develop duocarmycin based linker-drugs. After acquisition of Syntarga by Byondis in 2011, he led efforts in the field of protein chemistry and engineering which resulted in a novel site-specific conjugation technology (ByonShieLD), a dual payload ADC technology (ByonFoLD) and more recently a state-of-the-art antibody masking technology called ByonGuard.
Seminars
Monday 23rd February 2026
Introducing a Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs
1:30 pm
- Demonstrating rationale to develop masked ADCs to overcome challenges with target-mediated toxicity
- Highlighting development of ADCs leveraging masking technology including preclinical efficacy and safety profiles
- Looking ahead: What is the potential for masked ADC technology to deliver improved safety performance and therapeutic index?
